{"id":44938,"date":"2014-03-21T08:30:42","date_gmt":"2014-03-21T12:30:42","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=44938"},"modified":"2014-03-21T00:00:09","modified_gmt":"2014-03-21T04:00:09","slug":"champagne-around","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2014\/03\/21\/champagne-around\/","title":{"rendered":"champagne around…"},"content":{"rendered":"
\n
\n
Arkansas court tosses $1.2B judgment against J&J<\/a><\/div>\n
Associated Press<\/font><\/strong><\/div>\n
By CHUCK BARTELS<\/div>\n
Mar 20, 2014<\/div>\n

<\/p>\n

The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker’s marketing of the antipsychotic drug Risperdal. The court ruled that the state improperly sued under a law that applies to health care facilities, not pharmaceutical companies.<\/font><\/strong> The ruling comes in an appeal of lawsuit filed by Arkansas against the drugmaker and subsidiary Janssen Pharmaceuticals. The state says the companies didn’t properly communicate the drug’s risks and marketed it for off-label use, calling the practices fraudulent. Johnson & Johnson said there was no fraud and Arkansas’ Medicaid program wasn’t harmed…<\/div>\n
<\/div>\n
In a separate action brought by the U.S. Department of Justice, Johnson & Johnson agreed in November to pay more than $2.2 billion to federal and state governments and in penalties to resolve criminal and civil allegations that the company promoted powerful psychiatric drugs, including Risperdal, for unapproved uses in children, seniors and disabled patients. The agreement was the third-largest settlement with a drug maker in U.S. history.<\/div>\n
<\/div>\n
Johnson & Johnson and Janssen are also awaiting a ruling by the South Carolina Supreme Court, where the companies have an appeal pending of a $327 million judgment in a similar case. A $330 million verdict against both companies in Louisiana was overturned in January.<\/div>\n
hat tip to<\/font><\/strong> pharmagossip…<\/a> <\/div>\n<\/blockquote>\n
Matters legal and their vicissitudes are well beyond my skill set. But I think I get the music here. After their settlement in Texas, J&J lost a number of similar suits – Louisiana, South Carolina, Arkansas. Having sat through the Texas trial, it’s hard for me to imagine how they could win. The off-label marketing, hiding side effects, giving out perks, etc. It was just rampant. I think they settled in Texas because they could tell [as could everyone in the courtroom] that if they let the trial proceed, they stood the chance of getting massacred. But in the other suits, they went to the end – losing the verdicts. Now, they’re neutralizing their losses one at a time on technicalities. <\/div>\n

It will be champagne around in New Jersey at headquarters. Another bullet dodged by the hard [well paid] work by their lawyers. I reckon there have been many other champagne celebrations about Risperdal® in the past – pulling off TMAP, buying Omnicare’s business, Excerpta Medica’s flooding the medical literature, turning Biederman by funding a Harvard Center and cashing in on his Bipolar Child epidemic. The $ 2.2 B settlement with the feds was a set-back, but well within their cost of doing business budget. The Risperdal® roll-out was a big success for its leader Alex Gorsky, who is now CEO of the whole company. He turned a schizophrenia drug into an all-purpose blockbuster many times over. And he couldn’t have done it without the help of skillful lawyers and marketers. Well, that’s not the whole story.<\/p>\n

He also couldn’t have done it without the doctors who participated in creating the guidelines, and the treatment algorithms, and signed on to the articles, and acted as traveling speakers, and even wrote the prescriptions…<\/div>\n","protected":false},"excerpt":{"rendered":"

Arkansas court tosses $1.2B judgment against J&J Associated Press By CHUCK BARTELS Mar 20, 2014 The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker’s marketing of the antipsychotic drug Risperdal. The court ruled that the state improperly sued under a law that applies […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-44938","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/44938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=44938"}],"version-history":[{"count":6,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/44938\/revisions"}],"predecessor-version":[{"id":44944,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/44938\/revisions\/44944"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=44938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=44938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=44938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}